Precigen, Inc. (NASDAQ:PGEN – Get Rating) Director Randal J. Kirk bought 11,428,571 shares of Precigen stock in a transaction that occurred on Friday, January 27th. The stock was bought at an average cost of $1.75 per share, with a total value of $19,999,999.25. Following the completion of the purchase, the director now owns 31,129,164 shares in the company, valued at approximately $54,476,037. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Precigen Price Performance

Precigen stock opened at $1.62 on Wednesday. The firm has a 50-day moving average of $1.69 and a 200-day moving average of $1.92. The company has a market cap of $337.20 million, a price-to-earnings ratio of 13.50 and a beta of 1.89. Precigen, Inc. has a one year low of $1.12 and a one year high of $2.90.

Precigen (NASDAQ:PGEN – Get Rating) last issued its earnings results on Wednesday, November 9th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.10 by ($0.14). The firm had revenue of $16.72 million during the quarter, compared to the consensus estimate of $51.72 million. Precigen had a net margin of 33.55% and a negative return on equity of 82.23%. As a group, sell-side analysts expect that Precigen, Inc. will post -0.41 earnings per share for the current year.

Analyst Upgrades and Downgrades

Institutional Investors Weigh In On Precigen

A number of institutional investors and hedge funds have recently modified their holdings of PGEN. Renaissance Technologies LLC raised its holdings in shares of Precigen by 1,530.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,187,590 shares of the biotechnology company's stock valued at $2,506,000 after purchasing an additional 1,114,739 shares during the period. Marshall Wace LLP bought a new stake in shares of Precigen in the 3rd quarter valued at about $1,032,000. Goldman Sachs Group Inc. raised its holdings in shares of Precigen by 107.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 849,464 shares of the biotechnology company's stock valued at $1,792,000 after purchasing an additional 439,368 shares during the period. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of Precigen by 337.3% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 555,574 shares of the biotechnology company's stock valued at $1,178,000 after purchasing an additional 428,535 shares during the period. Finally, AXA S.A. raised its holdings in shares of Precigen by 1,582.4% in the 3rd quarter. AXA S.A. now owns 412,200 shares of the biotechnology company's stock valued at $874,000 after purchasing an additional 387,700 shares during the period.

About Precigen

(Get Rating)

Precigen, Inc is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases.

Featured Stories

• Get a free copy of the StockNews.com research report on Precigen (PGEN)
• Verizon, Charter Trend Higher In Past Month: Are They Buys Now?
• Dividend King Sysco: Buying On The Dip
• Is the 1,600% Rise in Genius Group Stock Justified?
• After Further Review, Investors Liked Exxon Mobil's Earnings
• Will Caterpillar Dig Its Way To Another Buying Opportunity?

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.